Consumer demand for cheap prescription drugs sold through spam-advertised Web sites shows no sign of abating, according to a new analysis of bookeeping records maintained by three of the world’s largest rogue pharmacy operations.
Researchers at the University of California, San Diego, the International Computer Science Institute and George Mason University examined caches of data showing the day-to-day finances of GlavMed, SpamIt, and Rx-Promotion, shadowy affiliate programs that over a four-year period processed more than $170 million worth of orders from customers seeking cheaper, more accessible and more discretely available drugs. The result is is perhaps the most detailed analysis yet of the business case for the malicious software and spam epidemics that persist to this day.